Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. SciClone Pharmaceuticals (Holdings) Limited
  6. News
  7. Summary
    6600   KYG4271B1023

SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED

(6600)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Sciclone Pharmaceuticals Limited Announces Unaudited Consolidated Financial Results for the Six Months Ended June 30, 2021

08/19/2021 | 08:02pm EST

SciClone Pharmaceuticals (Holdings) Limited announced unaudited consolidated financial results for the six months ended June 30, 2021. For the six months ended June 30, 2021, revenue was RMB 1,331,316,000 against RMB 1,160,982,000 for the same period of last year. Operating profit was RMB 698,474,000 against RMB 649,093,000 for the same period of last year. Profit for the period attributable to owners of the company was RMB 622,701,000 against RMB 597,110,000 for the same period of last year. Basic earnings per share was RMB 0.99 against RMB 1.10 for the same period of last year. Diluted earnings per share was RMB 0.92 against RMB 1.10 for the same period of last year.


ę S&P Capital IQ 2021
All news about SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
2021SciClone Pharmaceuticals Grants Nearly 4 Million Share Options
MT
2021SCICLONE PHARMACEUTICALS LIMITED(SEH : 6600) added to S&P Global BMI Index
CI
2021SCICLONE PHARMACEUTICALS : Wins License for Preclinical Miniature Solid Tumor Inhibitor
MT
2021Y MABS THERAPEUTICS : mAbs Announces Priorit Review of BLA for DANELZA (naxitamab-gqgk) in..
AQ
2021SCICLONE PHARMACEUTICALS : Gets Priority Review for Neuroblastoma Treatment in China
MT
2021NMPA Grants Priority Review to BLA of DANYELZA«
CI
2021610,329,800 Ordinary Shares of SciClone Pharmaceuticals Limited are subject to a Lock-U..
CI
2021Sciclone Pharmaceuticals Limited Announces Unaudited Consolidated Financial Results for..
CI
2021ThinkGeek Network Technology Files for Hong Kong IPO
MT
2021Beijing Evercare Medical Files for Hong Kong IPO
MT
More news
Financials
Sales 2021 2 437 M 384 M 384 M
Net income 2021 891 M 140 M 140 M
Net cash 2021 719 M 113 M 113 M
P/E ratio 2021 5,29x
Yield 2021 5,47%
Capitalization 4 726 M 745 M 745 M
EV / Sales 2021 1,64x
EV / Sales 2022 1,21x
Nbr of Employees 850
Free-Float -
Chart SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
Duration : Period :
SciClone Pharmaceuticals (Holdings) Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 7,00 CNY
Average target price 13,38 CNY
Spread / Average Target 91,0%
EPS Revisions
Managers and Directors
Hong Zhao President, CEO & Executive Director
Zhen Fu Li Chairman
Ping Chen Independent Non-Executive Director
Wendy Hayes Independent Non-Executive Director
Guo En Liu Independent Non-Executive Director
Sector and Competitors